This newsletter presents you the following key sessions:
1. Long-term follow-up subgroup analyses from JAVELIN Bladder 100 confirm avelumab first-line
maintenance activity regardless of the first-line chemotherapy regimen
2. Atezolizumab vs. chemotherapy in cisplatin-ineligible patients with advanced or metastatic
urothelial carcinoma highly expressing PD-L1
3. Comparative cost-effectiveness of alternative imaging and surveillance schedules for testicular seminoma
4. Abiraterone plus olaparib as a new first-line treatment option for patients with metastatic castration-
resistant prostate cancer
5. Gender specific differences in health-related quality of life for patients with bladder cancer following
radical cystectomy